Indeed, mice and melanoma patients with low frequencies of these tumor-associated myeloid subsets respond less favorably to anti-PD-1 and anti-CTLA-4 ICI and have worse overall clinical outcomes18,51. Here, CTLA4 is linked to melanoma.